Back to results
US 9,175,059 B2Granted
Anticancer fusion protein comprising trail and a growth factor receptor inhibitor
AssigneeAdamed Sp. z o.o.
InventorsJerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Żerek, Piotr Kamil Rózga
Life of this patent
Estimating the term…
Abstract
A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
Claims14
A fusion protein comprising:
- (i) domain (a) comprising a functional fragment of soluble human Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (hTRAIL) protein sequence starting with an amino acid in a position not lower than hTRAIL95 and ending with the amino acid at position hTRAIL281, or a homolog of said functional fragment having at least 70% sequence identity;
- and
- (ii) domain (b) comprising a sequence of an anti-angiogenic effector peptide, wherein said effector peptide is an inhibitor for growth factor receptor and is selected from the group of growth factor fragments consisting of a Vascular Endothelial Growth Factor (VEGF) fragment having the amino acid sequence set forth as SEQ ID NO:
- 17, a Platelet-Derived Growth Factor (PDGF) fragment having the amino acid sequence set forth as SEQ ID NO:
- 22, and an Epidermal Growth Factor (EGF) fragment having the amino acid sequence set forth as SEQ ID NO:
- 23;
- wherein the sequence of domain (b) is attached at C-terminus or N-terminus of domain (a).
4 more elements
Dependencies are inferred from the claim text.